Table 2 Medicine and LDL-C achieved at baseline and 4-year follow-up

LDL-C at 4 yr

 LDL-C value, mmol/L

2.87 [2.38, 3.39]

5.14 [4.21, 6.07]

< 0.001

2.94 [2.44, 3.46]

3.82 [3.17, 4.44]

< 0.001

 Absolute change in LDL-C at 4 yr, mmol/L

Ref

Ref

0.05 [−0.37, 0.46]

−1.68 [−2.74, −0.72]

< 0.001

 Percent change in LDL-C at 4 yr, (%)

Ref

Ref

2.0% [−12.1%, 17.4%]

−31.0% [−44.6%, −14.6%]

< 0.001

ASCVD risk assessment at baseline

 Ultra/Very high risk, n (%)

1,505 (13.9%)

38 (48.7%)

865 (12.6%)

28 (49.1%)

 High risk, n (%)

7,075 (65.4%)

40 (51.3%)

4,609 (66.9%)

27 (50.9%)

 Moderate risk, n (%)

962 (8.9%)

0 (0.0%)

593 (8.6%)

0 (0%)

 Low risk, n (%)

1,280 (11.8%)

0 (0.0%)

824 (12.0%)

0 (0%)

LDL-C achieved

 Achieve LDL-C target, n (%)

3,220 (29.5%)

0 (0.0%)

< 0.001

2,194 (27.2%)

2 (3.6%)

< 0.001

Ultra/Very high risk, n (% ^a)

49 (3.3%)

0 (0.0%)

29 (3.4%)

0 (0%)

High risk, n (%^a)

972 (13.7%)

0 (0.0%)

1,058 (23.0%)

2 (7.4%)

Moderate risk, n (%^a)

934 (97.0%)

0 (0.0%)

371(62.5%)

0 (0%)

Low risk, n (%^a)

1,265 (98.8%)

0 (0.0%)

736 (89.3%)

0 (0%)

 < 70 mg/dL (1.8 mmol/L)

646 (6.0%)

0 (0.0%)

< 0.001

331 (4.8%)

1 (1.8%)

0.126

 < 100 mg/dL (2.6 mmol/L)

3821 (35.3%)

1 (1.3%)

< 0.001

2,186 (31.7%)

7 (12.7%)

0.004